EGFR TKI sequencing: does order matter?
|
|
- Jody Conley
- 6 years ago
- Views:
Transcription
1 EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.
2 Disclosures Consultancy, symposia and research for Boehringer Ingelheim Consultancy, symposia, research and hospitality for Roche Consultancy, research and symposia for AstraZeneca 2
3 Afatinib Indications: In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable. Posology: The recommended dose is 40 mg once daily, orally. Maximum daily dose in squamous cell carcinoma of the lung is 50 mg, orally. Not recommended in patients with an egfr <15 ml/min, in patients requiring dialysis and in severe hepatic failure. 3
4 Choosing the sequence in EGFR-mutant NSCLC Evidence #1 TKIs are standard up front EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor. Girard. Future Oncol Epub ahead of print. 4
5 PFS (months) First- and second-generation EGFR TKIs are standard in the first-line treatment of NSCLC harbouring common EGFR mutations Better PFS versus platinum-based chemotherapy * * 10 * * Erlotinib Gefitinib* Afatinib Platinum-based chemotherapy *PFS not reported for common mutations only. EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor;. Gefitinib. Summary of Product Characteristics, 2010; Maemondo M, et al. N Engl J Med 2010;362:2380 8; Mitsudomi T, et al. Lancet Oncol 2010;11:121 8; Mok TS, et al. N Engl J Med 2009;361:947 57; Rosell, et al. Lancet Oncol 2012;13:239 46; Sequist, et al. J Clin Oncol 2013;31: ; Wu, et al. Lancet Oncol 2014;15:213 22; Wu, et al. Ann Oncol 2015;26:1883 9; Zhou, et al. Lancet Oncol 2011;12:
6 Choosing the sequence in EGFR-mutant NSCLC Evidence #1 TKIs are standard up front Evidence #2 Not all TKIs are equal Girard. Future Oncol Epub ahead of print. 6
7 First-, second- and third-generation EGFR TKIs are not equal: activity against EGFR mutations Wild-type EGFR Intrinsic mutant EGFR ErbB heterodimers, e.g. HER2: ErbB3 Acquired T790M EGFR K K K K K K K Erlotinib Gefitinib First-generation TKI EGFR inhibition Activity range Reversible binding to wild-type and mutant EGFR Inactive on T790M mutant Afatinib Dacomitinib Second-generation TKI ErbB family blockade Activity range Irreversible covalent binding to EGFR, ErbB2 and ErbB4 to inhibit all ErbB family signalling Broader activity to overcome EGFR TKI-resistant mutations Osimertinib Third-generation TKI EGFR mutant-specific inhibitor Activity Range Specificity for EGFR T790M mutant; EGFR wild-type sparing Irreversible covalent binding to mutant EGFR K Kinase domain 7 HER2, human epidermal growth factor 2. Girard. Future Oncol Epub ahead of print.
8 First-, second- and third-generation EGFR TKIs are not equal: activity against EGFR mutations T790M Wild-type 100 IC Wild-type T790M 1 EGFRm Wild-type EGFRm EGFRm T790M Gefitinib Afatinib Osimertinib Wild-type EGFR T790M EGFR mutant: L858R, exon 19 del IC 50, half-maximal inhibitory concentration. Cross, et al. Cancer Discov 2014;4: ; Hirano, et al. Oncotarget 2015;6: ; Li, et al. Oncogene 2008;27:
9 First-, second- and third-generation EGFR TKIs are not equal: metabolism Drug Enzymes involved in the metabolism of oral EGFR TKIs Metabolised by CYP enzymes 3A4 3A5 2D6 1A1 1A2 1B1 2C8 2C9 Gefitinib Erlotinib May inhibit CYP2C19 (w) CYP2D6 (w) UGT1A9, BRCP CYP3A4 (m) CYP2C8 (m) CYP1A1 (s) UGT1A1 (s) May induce Afatinib Dacomitinib CYP2D6 (s) CYP1A1 CYP1A2 Osimertinib BCRP CYP3A4 CYP1A2 CYP2C BCRP, breast cancer resistance protein; CYP, cytochrome P450 enzyme; UGT, UDP-glycosyltransferase. Cross, et al. Cancer Discov 2014;4: ; Li, et al. Oncogene 2008;27: ; Peters, et al. Cancer Treat Rev 2014;40:917 26; TAGRISSO. Prescribing Information, March
10 Choosing the sequence in EGFR-mutant NSCLC Evidence #1 TKIs are standard up front Evidence #2 Not all TKIs are equal Girard. Future Oncol Epub ahead of print. 10
11 Response rate (%) PFS (%) First- and second-generation EGFR TKIs are not equal: antitumour activity Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive NSCLC (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial p=0.002 p=0.150 p= % 75% 69% 66% 56% Afatinib (n=160) Gefitinib (n=159) Median, months HR (95% CI) p value 0.74 ( ) % % ITT Del19 L858R Afatinib Gefitinib CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat. Corral, et al. Ann Onc 2017;28(Suppl. 2):ii Afatinib Gefitinib 16% 16% 0 8% Months
12 Probability of PFS First- and second-generation EGFR TKIs are not equal: antitumour activity ARCHER 1050: Dacomitinib vs Gefitinib (excluding CNS metastases) ARCHER 1050: study design Phase III, randomised, open-label study to evaluate dacomitinib as an alternative first-line treatment for patients with advanced NSCLC with an EGFR-activating mutation Advanced NSCLC with EGFRactivating mutation(s) No prior systematic treatment of advanced NSCLC No CNS metastasis No prior EGFR TKI or other TKI ECOG PS 0, 1 R 1:1 (N=452) Satisfaction factors Race (including Asian vs non-asian) EGFR mutation type (exon 19 vs 21) Dacomitinib 45 mg PO QD (N=227) Gefitinib 250 mg PO QD (N=225) Primary endpoint PFS by blinded independent review 256 PFS events PFS HR (50% ) 90% power 1-sided ɑ=0.025 mpfs: 14.3 vs 9.5 months Secondary endpoints PFS (investigator assessed), ORR, DOR, TTF, OS, safety, PROs No. at risk Dacomitinib Gefitinib PFS: blinded independent review (ITT population) Number of events, n (%) Median PFS (95% Cl) HR (95% Cl) Daco (n=227) Gef (n=225) 136 (59.9%) 179 (79.6%) 14.7 ( ) 9.2 ( ) 0.59 ( ) p< PFS rate 30.6% vs 9.6% Months CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; PO, orally; QD, once daily; mpfs = median progression-free survival; ORR, objective response rate; DOR, duration of response; TTF, time to treatment failure; OS, overall survival; PRO, patient-reported outcome. ClinicalTrials.gov. (Accessed March 2018); Mok, et al. J Clin Oncol 2017;35(Suppl.): Abstract LBA9007; Wu, et al. Lancet Oncol 2017;18:
13 Probability of PFS First- and third-generation EGFR TKIs are not equal: antitumour activity PFS in FLAURA 1.0 Osimertinib (n=279) Erlotinib or gefitinib (n=277) Median PFS (95% Cl) 17.7 ( ) 9.7 ( ) HR (95% Cl) 0.45 ( ) p<0.001 Osimertinib Months No. at risk Osimertinib Erlotinib or Gefitinib Date cut-off 12 Jun Tick marks indicate censored data. Soria, et al. N Engl J Med 2018;378: First-generation EGFR TKI 13
14 First-, second- and third-generation EGFR TKIs do not have equal safety Second- or third-generation TKIs versus first-generation TKIs LUX-Lung 7 1,2 ARCHER FLAURA 4 Treatment discontinuation rate Afatinib (n=160) Gefitinib (n=159) Dacomitinib (n=227) Gefitinib (n=225) Osimertinib (n=279) Erlotinib or gefitinib (n=277) 6.2% 6.3% 9.7% 6.7% 10% 14% Most common Grade 3 AEs Diarrhoea 12% Rash/acne 9% Liver enzyme elevation 9% Rash/acne 3% Acne 14% Diarrhoea 8% Paronychia 7% Liver enzyme elevation 12% Dyspnoea 3% Diarrhoea 2% Decreased appetite 2% Rash/acne 7% Liver enzyme elevation 12% AE, adverse event. 1. Park, et al. Lancet Oncol 2016;17:577 89; 2. Paz-Ares, et al. Ann Oncol 2017;28:270 7; 3. Wu, et al. Lancet Oncol 2017;18: ; 4. Soria, et al. N Engl J Med 2018;378:
15 After reduction (<40 mg) Patients (%) Before reduction ( 40 mg) Patients (%) Estimated PFS probability Dose reduction of afatinib reduced drug-related AEs without compromising efficacy Treatment-related AEs in patients who had a dose reduction from 40 mg (n=63) Any Diarrhoea Rash/acne Stomatitis Nail effect PFS in patients who received a dose reduction within the first 6 months of treatment Median, months HR (95% CI) p value <40 mg in first 6 months (n=47) 40 mg for first 6 months (n=113) ( ) All grades Grade Any Diarrhoea Rash/acne Stomatitis Nail effect Hirsh, et al. J Clin Oncol 2016;34(Suppl.): Abstract Months No. at risk: <40 mg mg
16 Choosing the sequence in EGFR-mutant NSCLC Evidence #1 TKIs are standard up front Evidence #2 Not all TKIs are equal Evidence #3 Biology drives sequence Girard. Future Oncol Epub ahead of print. 16
17 First-line: PFS efficacy of TKIs is different in EGFR del19/l858r mutations Impact of specific EGFR mutations and clinical characteristics on outcomes after treatment with EGFR TKIs versus chemotherapy in EGFRm+ lung cancer: a meta-analysis Trial HR 95% Cl HR 95% Cl Exon 19 deletions Exon 21 L858R substitution ENSURE EURTAC LUX-Lung LUX-Lung NEJ OPTIMAL WJTOG AII TKI Chemotherapy TKI Chemotherapy EGFRm+, epidermal growth factor receptor mutation positive. Lee, et al. J Clin Oncol 2015;33:
18 First-line: OS Efficacy of TKIs Is Different in EGFR del19/l858r Mutations Agent Study HR (95% CI) Del19 HR (95% CI) L858R LUX-Lung ( ) 1.30 ( ) Afatinib Erlotinib Gefitinib LUX-Lung ( ) 1.22 ( ) Total 0.59 ( ) Favours afatinib Favours chemotherapy 1.25 ( ) ENSURE 0.79 ( ) 1.05 ( ) EURTAC 0.94 ( ) 1.00 ( ) OPTIMAL 1.52 ( ) 0.92 ( ) Total 1.04 ( ) Favours erlotinib Favours chemotherapy 0.98 ( ) IPASS 0.86 ( ) 1.40 ( ) NEJ ( ) 0.82 ( ) WJTOG ( ) 1.11 ( ) Favours afatinib Favours chemotherapy Favours erlotinib Favours chemotherapy Total 0.90 ( ) ( ) Favours gefitinib Favours chemotherapy Favours gefitinib Favours chemotherapy Kato, et al. Value Health 2015;18:A436 (Abstract PCN40). 18
19 Maximum change from baseline (%) First-line: afatinib is effective for uncommon EGFR mutations Clinical activity of afatinib in patients with advanced NSCLC harbouring uncommon EGFR mutations: a combined post hoc analysis of LUX-Lung 2, 3, and Group 1 (n=33): Exon 18-21: G719, L861Q Group 2 (n=14): T790M mutations Group 3 (n=20): Exon 20 insertions PFS (months) Response rate (%) T790M (n=14) Exon 20 ins (n=23) Mut/ dup exon (n=38) G719X (n=18) L861Q (n=16) S768I (n=8) PFS (months) OS (months) NE Note: A patient may be presented in more than one category Patient index sorted by maximum percent decrease in descending order Yang, et al. Lancet Oncol 2015;16:
20 Choosing the sequence in EGFR-mutant NSCLC Evidence #1 TKIs are standard up front Evidence #2 Not all TKIs are equal Evidence #3 Biology drives sequence Girard. Future Oncol Epub ahead of print. 20
21 Molecular mechanisms of acquired resistance to first-/second-generation EGFR TKIs HER2 8% 155 EGFR-mutant NSCLC patients, acquired resistance after TKI Molecular analyses on re-biopsy specimen MET amplification 3% Small cell + MET 1% Small cell 1% Small cell + T790M 2% MET + T790M 3% Unknown 18% T790M 60% HER2 T790M 4% 21 MET, MET proto-oncogene. Yu, et al. Clin Cancer Res 2013;19:
22 Molecular mechanisms of acquired resistance to first-/second-generation EGFR TKIs Initial diagnosis J170 Relapse 12.74% 29.04% 5.10% ETV6, WNK1-WAC, MYO18B 53.21% Chemotherapy Type cellulaire Normal AML Mutations Funding Activating Mutation Recurrence Resistance Passenger Pathogenic 22 HSC, haematopoietic stem cell. Ding, et al. Nature 2015;481:
23 Probability of PFS Osimertinib standard of care for T790M+ acquired resistance to first-/second-generation EGFR TKIs Patients in the population 1.0 No. at risk Osimertinib Platinum-pemetrexed Month Platinum-pemetrexed Osimertinib No. of patients Median PFS (months) (95% CI) Osimertinib ( Platinum-pemetrexed ( ) HR for PD or death, 0.30 (95% CI: ) p< PD, progressive disease. Mok, et al. N Engl J Med 2017;376:
24 Choosing the sequence in EGFR-mutant NSCLC Evidence #1 TKIs are standard up front Evidence #2 Not all TKIs are equal Evidence #4 Biological monitoring is key Evidence #3 Biology drives sequence Girard. Future Oncol Epub ahead of print. 24
25 Identification of T790M at acquired resistance, is tissue re-biopsy feasible? Prospective, multicentre, real-world study: Re-biopsy methods Surgery Adrenalectomy 1 Lung surgery 3 Node surgery 1 Cytology Nodes 3 Pleura 2 (n=82) Biopsy Bronchial + E-BUS 43 Pulmonary under CT 19 Liver 2 Bone 6 Skin 2 Retrospective, single-centre study: EGFRm+ NSCLC: PD after EGFR TKI (n=139) Eligible for third-generation EGFR TKI (n=120; 86%) Re-biopsy (n=75) Pathologic diagnosis (n=71; 95%) EGFR mutation analysis (n=61) Ineligible for trial: poor PS: n=10; comorbidity: n=7; elderly: n=2 Ineligible for re-biopsy: inaccessible tumour sites: n=19 (18 brain metastases and one lung lesion <20 mm); physician decision: n=10 patient refusal: n=6 unknown: n=10 Re-biopsy could not be done in 18% of cases, mainly because of anticoagulation that the patient s physician considered to be a contraindication. One patient refused re-biopsy. Among the 82 patients who underwent re-biopsy, the sample could be analysed histologically in 94% of cases. Cytologic samples represented only. Chouaid, et al. Lung Cancer 2014;86:170 3; Kawamura T, et al. Cancer Sci 2016;107: T790M (n=20; 33%) 25
26 Proposed algorithm for use of plasma genotyping for EGFR T790M A Acquired resistance to EGFR TKI All patients undergo biopsy, FDA-approved FFPE assay for T790M T790M+ T790M Third-generation EGFR TKI Chemotherapy B Acquired resistance to EGFR TKI FDA-approved plasma assay for T790M and sensitising mutations T790M+ T790M Skip biopsy, start third-generation EGFR TKI Biopsy, FDA-approved FFPE assay for T790M T790M+ T790M Third-generation EGFR TKI Chemotherapy FDA, US Food and Drug Administration; FFPE, formalin-fixed, paraffin-embedded. Oxnard, et al. J Clin Oncol 2016;34:
27 Choosing the sequence in EGFR-mutant NSCLC Evidence #1 TKIs are standard up front Evidence #5 Sequence makes survival Evidence #2 Not all TKIs are equal Evidence #4 Biological monitoring is key Evidence #3 Biology drives sequence Girard. Future Oncol Epub ahead of print. 27
28 What is OS in EGFR-mutant NSCLC? Number of lines x Addition of the PFS of all treatment lines TKIs, chemotherapy, other At each patient level: NEED for the swimmer plot of individual patients NOT the sum of median PFS in trials 28
29 Treatment sequences in EGFR-mutant NSCLC after first-line EGFR TKI First-/secondgeneration TKI Chemotherapy First-/secondgeneration TKI Girard. Future Oncol Epub ahead of print. 29
30 Estimated OS (probability) OS in EGFR-mutant NSCLC: LUX-LUNG 3 trial Common mutations (Del19/L858R) (n=307) Afatinib Cisplatin/pemetrexed Median, months Common mutations Afatinib (n=203) Cis/Pem (n=104) No. at risk: Afatinib Cis/Pem Yang, et al. Ann Oncol 2015;16: HR (95% CI) 0.78 ( ) OS (months)
31 Treatment sequences in EGFR-mutant NSCLC after first-line EGFR TKI T790M+ Osimertinib Chemotherapy? TKI? First-/secondgeneration TKI Except if molecular target Girard. Future Oncol Epub ahead of print. 31
32 AURA3: treatment beyond osimertinib Ongoing osimertinib treatment at time of data cut-off (n=166) Discontinue treatment (n=113) Objective PD (n=77) AE (n=18) Subject decision (n=9) Other (n=8) Severe protocol non-compliance (n=1) Anticancer treatment post-discontinuation of osimertinib (n=67) Platinum-containing chemotherapy regimen (n=48) Non-platinum-containing chemotherapy regimen (n=18) Radiotherapy (n=17) EGFR TKI (n=9) EGFR TKI + non-pd-1/pd-l1 (n=6) PD-1/PD-L1 (n=4) PD-1, programmed death-1; PD-L1, programmed death ligand-1. Mok, et al. N Engl J Med 2017;376:
33 Treatment sequences in EGFR-mutant NSCLC after first-line EGFR TKI T790M+ Osimertinib Chemotherapy? TKI? First-/secondgeneration TKI Except if molecular target T790M Chemotherapy First-/secondgeneration TKI Other MET/HER2 inhibitor Girard. Future Oncol Epub ahead of print. 33
34 Treatment sequences in EGFR-mutant NSCLC after first-line EGFR TKI T790M+ Osimertinib Chemotherapy? TKI? First-/secondgeneration TKI Except if molecular target T790M Chemotherapy First-/secondgeneration TKI Other MET/HER2 inhibitor FACT #1: OS DATA FROM AURA-3 NOT YET AVAILABLE Girard. Future Oncol Epub ahead of print. 34
35 Treatment sequences in EGFR-mutant NSCLC after first-line EGFR TKI T790M+ Osimertinib Chemotherapy? TKI? First-/secondgeneration TKI Except if molecular target T790M Chemotherapy First-/secondgeneration TKI Other MET/HER2 inhibitor FACT #2: CHALLENGE IS TO ENSURE ACCESS FOR A MAJORITY OF PATIENTS TO FURTHER LINES OF TREATMENT Girard. Future Oncol Epub ahead of print. 35
36 Estimated OS probability OS in patients treated with osimertinib subsequently in LUX-Lung 3, 6 and Median follow-up = 4.7 years No. at risk: Time to death (months) Afatinib Sequist, et al. Ann Oncol 2017;28(Suppl. 5): v460-v /annonc/mdx380 36
37 Estimated PFS probability Estimated PFS probability Analysis of treatment sequence: first-/secondgeneration TKIs followed by third-generation TKIs Median PFS in LUX-Lung months with afatinib 10.9 months with gefitinib OS in patients treated with osimertinib subsequently in LUX-Lung 3, 6, and Afatinib Gefitinib Time of PFS (mo) Median PFS in AURA-3 (T790M+) months with osimertinib 0.6 Osimertinib Platinum-pemetrexed Months Sequist, et al. Ann Oncol 2017;28(Suppl. 5): v460-v /annonc/mdx380; Mok TS, et al. N Engl J Med 2017;376:629 40; Park K, et al. Lancet Oncol. 2016;17:
38 Treatment sequences in EGFR-mutant NSCLC after first-line EGFR TKI First-/secondgeneration TKI T790M+ T790M Osimertinib Chemotherapy Chemotherapy Except if molecular target First-/secondgeneration TKI Other MET/HER2 inhibitor Osimertinib Girard. Future Oncol Epub ahead of print. 38
39 FLAURA: treatment beyond osimertinib Regimen Osimertinib (n=279) Erlotinib or gefitinib (n=277) First post-treatment anticancer therapy (including crossover osimertinib), n (%) Discontinued randomised trial treatment 138 (49) 213 (77) First post-treatment anticancer therapy 82 (29) 129 (47) No post-treatment anticancer therapy 56 (20) 84 (30) Ongoing randomised trial treatment 141 (51) 64 (23) First post-treatment anticancer therapy, n (%) EGFR-TKI 29 (21) 97 (46) PD-1/PD-L1 3 (2) 2 (1) Non-platinum chemotherapy 50 (36) 27 (13) Platinum-based chemotherapy 48 (35) 26 (12) Other targeted therapy 2 (1) 3 (1) Anti-VEGF 7 (5) 4 (2) Second post-treatment anticancer therapy, n (%) Second post-treatment anticancer therapy 24 (9) 39 (14) Only one post-treatment anticancer therapy 58 (21) 90 (32) Second post-treatment anticancer therapy, n (%) EGFR TKI 10 (7) 14 (7) PD-1/PD-L1 2 (1) 1 (<1) Non-platinum chemotherapy 11 (8) 19 (9) Platinum-based chemotherapy 4 (3) 16 (8) Other targeted therapy 1 (1) 2 (1) Anti-VEGF 3 (2) 6 (3) VEGF, vascular endothelial growth factor. Soria, et al. N Engl J Med 2018;378:
40 FLAURA: treatment beyond osimertinib Regimen Osimertinib (n=279) Erlotinib or gefitinib (n=277) First post-treatment anticancer therapy (including crossover osimertinib), n (%) Discontinued randomised trial treatment 138 (49) 213 (77) First post-treatment anticancer therapy 82 (29) 129 (47) No post-treatment anticancer therapy 56 (20) 84 (30) Ongoing randomised trial treatment 141 (51) 64 (23) First post-treatment anticancer therapy, n (%) EGFR-TKI 29 (21) 97 (46) PD-1/PD-L1 3 (2) 2 (1) Non-platinum chemotherapy 50 (36) 27 (13) Platinum-based chemotherapy 48 (35) 26 (12) Other targeted therapy 2 (1) 3 (1) Anti-VEGF 7 (5) 4 (2) Second post-treatment anticancer therapy, n (%) Second post-treatment anticancer therapy 24 (9) 39 (14) Only one post-treatment anticancer therapy 58 (21) 90 (32) Second post-treatment anticancer therapy, n (%) EGFR TKI 10 (7) 14 (7) PD-1/PD-L1 2 (1) 1 (<1) Non-platinum chemotherapy 11 (8) 19 (9) Platinum-based chemotherapy 4 (3) 16 (8) Other targeted therapy 1 (1) 2 (1) Anti-VEGF 3 (2) 6 (3) VEGF, vascular endothelial growth factor. Soria, et al. N Engl J Med 2018;378:
41 Treatment sequences in EGFR-mutant NSCLC after first-line EGFR TKI First-/secondgeneration TKI T790M+ T790M Osimertinib Chemotherapy Chemotherapy Except if molecular target First-/secondgeneration TKI Other MET/HER2 inhibitor Osimertinib Chemotherapy Except if molecular target Girard. Future Oncol Epub ahead of print. 41
42 Treatment sequences in EGFR-mutant NSCLC after first-line EGFR TKI First-/secondgeneration TKI T790M+ T790M Osimertinib Chemotherapy Chemotherapy Except if molecular target First-/secondgeneration TKI Other MET/HER2 inhibitor Osimertinib Chemotherapy Except if molecular target NEED MATURE OS AND TREATMENT SEQUENCES FROM FLAURA Girard. Future Oncol Epub ahead of print. 42
43 How to optimise sequence? Clinical factors CNS disease and progression Loss of patients from one line to another Treatment beyond progression Optimisation of treatments Anti-angiogenics Anti-EGFR antibodies Understanding of biology Resistance mechanisms to sequencing versus osimertinib Impact of de novo T790M 43
44 Molecular characterization after osimertinib first-line failure (all T790M negative) Kras and EGFR ampl 11% Kras 11% C797S 23% Baselin mutatio Ex19de Ex19de L858R PIK3CA 11% JAK2 11% Mek 11% Met ampl 11% Her2 mut 11% Ex19de Ex19de L858R a T790M Ex19de G719S S768I L858R Ramalingam, et al. J Clin Oncol 2018;36:
45 Choosing the sequence in EGFR-mutant NSCLC Evidence #1 TKIs are standard up front Evidence #5 Sequence makes survival Evidence #2 Not all TKIs are equal Evidence #4 Biological monitoring is key Evidence #3 Biology drives sequence Girard. Future Oncol Epub ahead of print. 45
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationMaking the first decision: EGFR mutation-positive NSCLC in the advanced setting
ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain Disclosures Consultant or Advisory Role
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationIMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC:
IMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC: A focus on EGFR-inhibition and implications for clinical practice Floriana Morgillo, MD PhD and Morena Fasano, MD PhD Faculty of Medicine, Università degli
More informationOsimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationNext-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
BioDrugs (2015) 29:167 183 DOI 10.1007/s40259-015-0130-9 REVIEW ARTICLE Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib Vera Hirsh 1 Published online: 30 June 2015 The
More informationAFATINIB* 1. WHAT IS AFATINIB? 2. HOW DOES AFATINIB WORK? B A C K G R O U N D E R
AFATINIB* B A C K G R O U N D E R 1. What is afatinib? 2. How does afatinib work? 3. Data overview: the LUX-Lung clinical trial programme 4. Data overview: the LUX-Head and Neck clinical trial programme
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan;
Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7 James C.-H. Yang, 1 Yi-Long Wu, 2 Vera Hirsh,
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationNext Generation EGFR Inhibitors
Next Generation EGFR Inhibitors Tony Mok MD Li Shu Fan Medical Foundation Professor of Clinical Oncology Dept. of Clinical Oncology The Chinese University of Hong Kong EGFR TKIs First Generation -Gefitinib
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationPresented at the European Society of Medical Oncology (ESMO), Munich, Germany, October 2018
Effectiveness of afatinib in clinical practice first results of the GIDEON trial: a prospective non-interventional study in EGFR-mutated NSCLC in Germany Wolfgang M. Brueckl 1 *, Eckart Laack 2, Martin
More informationTKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad
TKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad Dra Pilar Lianes Barragan Consorcio Sanitario del Maresme (Barcelona) Indice Epidemiología TKI en primera línea Eficacia
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationEGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI
EGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI 217 Conversations in Oncology in Shanghai, China Dr. Daniel SW Tan Division of Medical Oncology, National Cancer Centre
More informationPost-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report)
Post-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report) Nobuyuki Yamamoto, 1 Toshihiro Nukiwa, 2 Yoichi Nakanishi,
More informationGIOTRIF (AFATINIB*) For journalists outside the US/UK/Canada only 1. WHAT IS GIOTRIF (AFATINIB*)? 2. HOW DOES GIOTRIF (AFATINIB*) WORK?
For journalists outside the US/UK/Canada only GIOTRIF (AFATINIB*) 1. What is GIOTRIF (afatinib*)? 2. How does GIOTRIF (afatinib*) work? 3. Data overview 4. Clinical potential 5. GIOTRIF (afatinib*) approval
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationOverall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationJ. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer J. C.-H. Yang 1, L.V. Sequist
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationB I ABOUT BI DISEASE AREA & MECHANISM OF ACTION. For journalists outside UK/US/Canada only B A C K G R O U N D E R
For journalists outside UK/US/Canada only B I 1 4 8 2 6 9 4 1. About BI 1482694 2. Disease area & mechanism of action 3. Development status 4. Data overview 1. ABOUT BI 1482694 BI 1482694* (HM61713**)
More informationTechnology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer Technology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationMaximising Clinical Benefit from TKIs in the Treatment of Advanced NSCLC
Maximising Clinical Benefit from TKIs in the Treatment of Advanced NSCLC 2017 WCLC- PACIFICO Yokohama Convention Center 16 October, 2017 BI symposium Meeting Welcome and Introductions 2017 WCLC- PACIFICO
More informationRociletinib (CO-1686) April, 2015
Rociletinib (CO-1686) April, 2015 Lung adenocarcinoma is increasingly treated according to driver mutation Lung cancer incidence Worldwide: 1.2M cases per year UK: 43K cases per year Activating mutations
More informationYan Zhang 1*, Zheng Wang 2*, Xuezhi Hao 1, Xingsheng Hu 1, Hongyu Wang 1, Yan Wang 1, Jianming Ying 3. Original Article. Abstract
Original Article Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations Yan Zhang
More informationCompeting CNS or systemic progression analysis for EGFR mutation-positive NSCLC patients on afatinib in LUX-Lung 3, 6, and 7
Competing CNS or systemic progression analysis for EGFR mutation-positive NSCLC patients on afatinib in LUX-Lung 3, 6, and 7 Diego Kaen, 1 James C.-H. Yang, 2 Yi-Long Wu, 3 Vera Hirsh, 4 Kenneth O Byrne,
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationManagement of EGFR-mutant NSCLC. Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center
Management of EGFR-mutant NSCLC Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center Disclosures Research Funding: Merck, Novartis, AstraZeneca, Millenium Consulting: AbbVie,
More informationSecond-line afatinib for advanced squamous cell carcinoma of the lung: analysis of afatinib long-term responders in the Phase III LUX-Lung 8 trial
Second-line afatinib for advanced squamous cell carcinoma of the lung: analysis of afatinib long-term responders in the Phase III LUX-Lung 8 trial lenwood oss, Manuel Cobo, Shun Lu, Konstantinos Syrigos,
More informationEpidermal growth factor receptor (EGFR) mutations are
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 Terufumi Kato, 1 Hiroshige Yoshioka,
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationORIGINAL ARTICLE. Oncology and Translational Medicine DOI /s Abstract
Oncology and Translational Medicine DOI 10.1007/s10330-018-0281-1 August 2018, Vol. 4, No. 4, P158 P162 ORIGINAL ARTICLE Treatment and survival status of patients with EGFR mutation-positive stage IV lung
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationAURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationUncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased
Original Article Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased chemotherapy Jinpeng Shi 1*, Hui Yang 1*, Tao Jiang 1, Xuefei Li 2,
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationSequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
Scan the QR code for an electronic copy of the poster and supplementary material Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the
More informationMolecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
More informationAfatinib in advanced NSCLC: a profile of its use
Drugs Ther Perspect (2018) 34:89 98 https://doi.org/10.1007/s40267-018-0482-6 ADIS DRUG Q&A Afatinib in advanced NSCLC: a profile of its use Emma D. Deeks 1 Gillian M. Keating 1 Published online: 1 February
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationConsiderations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
metastases were similar to the overall trial results, leading perc to conclude that osimertinib should be made available to patients with stable CNS metastases. Furthermore, perc noted that patients with
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationCorrespondence should be addressed to Kumar Prabhash;
Hindawi Chemotherapy Research and Practice Volume 2017, Article ID 8196434, 4 pages https://doi.org/10.1155/2017/8196434 Clinical Study Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationS. Morin Ben Abdallah md* and V. Hirsh md* REVIEW ARTICLE ABSTRACT INTRODUCTION. Key Words tkis, afatinib
REVIEW ARTICLE AFATINIB IN EGFR ACTIVATING MUTATION POSITIVE ADVANCED NSCLC, Morin Ben Abdallah and Hirsh Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR
More informationSummary of the risk management plan (RMP) for Tagrisso (osimertinib)
EMA/2497/2016 Summary of the risk management plan (RMP) for Tagrisso (osimertinib) This is a summary of the risk management plan (RMP) for Tagrisso, which details the measures to be taken in order to ensure
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationManagement of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer
Management of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center Rogerio Lilenbaum, MD Yale Cancer Center/Smilow Cancer Hospital EGFR Mutation
More informationAFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationOsimertinib (lung cancer)
IQWiG Reports Commission No. A16-14 Osimertinib (lung cancer) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Osimertinib
More informationIntroduction. Methods. Patient and study design
Original Article Continuation of gefitinib plus chemotherapy prolongs progressionfree survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More information